Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Bioneer Deal May Point To Yuhan R&D Strategy Change

This article was originally published in PharmAsia News

Executive Summary

Yuhan has been seen as one of the less aggressive South Korean pharma firms in terms of beefing up R&D. But now, the company may be shifting its strategy as it has decided to become the second biggest shareholder of local bioventure Bioneer, in a move to strengthen its pipeline including immuno-oncology drugs and to diversify into new businesses.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC089212

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel